1. Introduction
===============

Atrial fibrillation (AF) is the most common type of cardiac arrhythmia which increases the risk of ischemic stroke 4 to 5 fold \[[@B1-healthcare-03-00130]\]. Oral anticoagulants (OACs) are more effective than aspirin in reducing the stroke risk, but are also associated with an increased bleeding risk. Therefore, anticoagulant recommendations depend upon balancing the expected benefit of stroke risk reduction against the increased harm from bleeding in patients with different factors that are prognostic for strokes and bleeding \[[@B2-healthcare-03-00130]\].

Several studies have shown that anticoagulant prescribing is often poorly related to patient stroke risk with underuse of anticoagulants in AF being more common, especially among elevated stroke risk patients \[[@B3-healthcare-03-00130],[@B4-healthcare-03-00130],[@B5-healthcare-03-00130]\]. One of the reasons for the under use of anticoagulants is the variation in physicians' perceptions of the relative risk of stroke compared to bleeding by their specialty \[[@B6-healthcare-03-00130]\]. Physicians with a good personal experience with warfarin are more likely to prescribe warfarin; however, even these physicians prescribe warfarin in only half of their warfarin eligible AF patients \[[@B7-healthcare-03-00130]\]. Oral anticoagulants are not only underused but are also overused in the patients with low stroke risk \[[@B8-healthcare-03-00130]\].

Given the evidence of inappropriate OAC prescribing, various AF guidelines and decision support tools have been developed to aid clinicians considering oral anticoagulants for their AF patients. These decision aids include various clinical guidelines, model based decision tools and electronic medical record based apps and tools. However, these guidelines and decision support tools do not use the same stroke and bleed risk algorithms for treatment recommendations ([Table S1](#healthcare-03-00130-s001){ref-type="supplementary-material"}) \[[@B9-healthcare-03-00130],[@B10-healthcare-03-00130],[@B11-healthcare-03-00130],[@B12-healthcare-03-00130],[@B13-healthcare-03-00130],[@B14-healthcare-03-00130],[@B15-healthcare-03-00130],[@B16-healthcare-03-00130]\]. All the contemporary decision aids rely on the CHADS~2~ or the CHA~2~DS~2~-VASc scores to estimate stroke risk \[[@B17-healthcare-03-00130],[@B18-healthcare-03-00130]\]. Some tools include formal bleed risk assessments including HAS-BLED and ATRIA, which are validated tools to estimate bleeding risk in AF patients \[[@B19-healthcare-03-00130],[@B20-healthcare-03-00130]\]. The differences in the preferences for the stroke/bleed risk algorithm by these decision aids are due to the differences in the expert opinion and/or a lack of sufficient evidence supporting use of one approach over the other. The 2012 American College of Chest Physicians (CHEST) guideline recommendations are solely based on the stroke risk (CHADS~2~) scores as they have been extensively validated and easy for clinicians to remember, whereas the 2012 European Society of Cardiology (ESC) guidelines and the 2014 American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society (AHA/ACC/HRS hereafter "AHA") guideline recommendations are based on CHA~2~DS~2~-VASc \[[@B10-healthcare-03-00130],[@B12-healthcare-03-00130],[@B13-healthcare-03-00130]\]. Existing evidence suggest that the CHA~2~DS~2~-VASc has a better ability to identify patients who are at "truly low stroke risk" with a comparable overall discriminative ability in predicting ischemic stroke when compared to CHADS~2~ score \[[@B13-healthcare-03-00130]\]. Two published decision tools by Casciano *et al.* (hereafter "Casciano tool") and LaHaye *et al.* (hereafter "Lahaye tool") also include bleed risk scores (Casciano based on ATRIA, LaHaye based on HAS BLED) along with the stroke risk scores (Casciano based on CHADS~2~, LaHaye based on CHA~2~DS~2~-VASc) to derive their treatment recommendations. The tool developers did not provide a justification for choice of one bleed risk score over the other but this could be due to the lack of studies comparing the two bleed risk algorithms when the decision tools were developed \[[@B9-healthcare-03-00130],[@B11-healthcare-03-00130]\].

Currently, there are no population-based studies that have compared the treatment recommendations by the AF guidelines and decision support tools. To address this, we empirically compared the treatment recommendations by the 2012 CHEST guidelines, the 2012 ESC guidelines, the 2014 AHA guidelines, the Casciano tool and the LaHaye tool \[[@B9-healthcare-03-00130],[@B10-healthcare-03-00130],[@B11-healthcare-03-00130],[@B12-healthcare-03-00130],[@B13-healthcare-03-00130]\]. To compare the acceptance of the guideline and decision tool recommendations in real world practice, we compared the concordance of actual OAC use/non-use between the decision aid recommendations. To understand the differences in the treatment recommendations by the decision aids and their concordance with actual OAC use/non-use at a more granular level, we also stratified our study population by their baseline stroke and bleed risk.

2. Methods
==========

2.1. Study Design
-----------------

A cross sectional study design using incident cases of AF from a 10% sample of the Lifelink claims database from 2001 to 2013 was used to contrast the treatment recommendations by these decision aids. The Lifelink claims data is nationally representative of the commercially insured population with respect to age, gender, geographic location and the type of insurance coverage. Separate files for inpatient claims, outpatient claims, prescription claims and eligibility data are available in the database. The inpatient and outpatient claim files include diagnosis codes in the International Classification of Disease, 9th Revision, Clinical Modification (ICD-9-CM) format as well as procedure codes in the Healthcare Common Procedure Coding System (HCPCS) format. The prescription claim files include data on national drug code (NDC) level and represents prescriptions covered by the insurance plan. The eligibility file was used to determine monthly enrolment/disenrollment in health plans. This study was approved by the University of Arkansas for Medical Sciences Institutional Review Board.

2.2. Study Subjects
-------------------

The first primary diagnosis of AF was defined as the index diagnosis. Patients without any AF related claim within 12 months before the index diagnosis were defined as incident cases of AF. To rule out transient AF cases, we required patients to have at least two AF related claims separated by 30 days and have at least one outpatient claim with primary AF diagnosis in the post index period. Patients were also required to have continuous medical and pharmacy benefit eligibility for at least 12 months prior and three months after the index diagnosis. [Table S2](#healthcare-03-00130-s001){ref-type="supplementary-material"} shows a flowchart depicting the details of inclusion-exclusion criteria applied for the selection of final study sample.

2.3. Exposure Definition
------------------------

The Lifelink claims database does not completely capture over-the-counter (OTC) aspirin use. Also, the newer oral anticoagulants were not available during most of the study time period. Therefore, the exposure definition was limited to oral anticoagulant (OAC) exposed and unexposed. A patient with at least one prescription claim for an oral anticoagulant (warfarin, dabigatran, apixaban or rivaroxaban) within 90 days of index diagnosis or at least one International Normalized Ratio/Prothrombin Time (INR/PT) claim within 90 days of the index diagnosis followed by a second INR/PT claim within 90 days of the first INR/PT claim date was considered as an OAC exposed patient. INR/PT test is often used as a proxy for warfarin exposure \[[@B21-healthcare-03-00130],[@B22-healthcare-03-00130]\]. Patients who did not meet the definition of OAC exposure (including aspirin users) were considered as OAC unexposed patients.

2.4. Stroke Risk and Bleeding Risk
----------------------------------

We calculated the stroke risk and bleeding risk using two stroke risk (CHADS~2~ and CHA~2~DS~2~-VASc) and two bleeding risk (ATRIA and HAS-BLED) algorithms. The operational definition to calculate stroke and bleeding risk scores were obtained from previous studies using administrative claims data \[[@B9-healthcare-03-00130],[@B23-healthcare-03-00130],[@B24-healthcare-03-00130],[@B25-healthcare-03-00130]\].

2.5. Decision Aid Recommendations
---------------------------------

The Casciano recommendations are based on the CHADS~2~ score, ATRIA score, patient characteristics (age and gender) to estimate the quality-adjusted life expectancy with warfarin/aspirin treatment \[[@B11-healthcare-03-00130]\]. The LaHaye tool offers treatment recommendations for aspirin, warfarin and newer oral anticoagulants based on the CHA~2~DS~2~-VASc score, HAS-BLED score, a treatment threshold (minimum stroke risk reduction after initiating antithrombotic therapy), a cost threshold (maximum cost that a patient is willing to pay per day in order to realize the specified treatment threshold) and bleed ratio (maximum number of major bleed events that a patient can endure to prevent one stroke event). Our analysis was restricted to warfarin and aspirin (ASA) recommendations of the LaHaye tool that were obtained by using fixed values of the treatment threshold (0.3%), the cost threshold (\$0.50) and the bleed ratio (2:1) \[[@B9-healthcare-03-00130]\]. The CHEST guideline recommendations are based on the CHADS~2~ score while the ESC and the AHA guideline recommendations are based on the CHA~2~DS~2~-VASc algorithm \[[@B10-healthcare-03-00130],[@B12-healthcare-03-00130],[@B13-healthcare-03-00130]\]. The ESC guideline recommends caution for prescribing OAC when HAS BLED ≥ 3. To operationalize the ESC OAC recommendation, we set the ESC guideline to recommend withholding OAC in patients with CHA~2~DS~2~-VASc score = 1 and HAS BLED ≥ 3, and OAC in patients whose HAS-BLED score is less than 3 and CHA~2~DS~2~-VASc score = 1, and OAC in all patients when CHA~2~DS~2~-VASc score \> 1 \[[@B13-healthcare-03-00130]\]. The AHA guideline does not offer a clear recommendation for OAC in patients when CHA~2~DS~2~-VASc score = 1. Therefore, we compared two scenarios: (i) conservative OAC AHA recommendations which assume that OAC is not recommended (AHA Conservative) and (ii) aggressive OAC AHA recommendations which assume that OAC is recommended (AHA Aggressive) when CHA~2~DS~2~-VASc score = 1 \[[@B10-healthcare-03-00130]\].

2.6. Main Independent Variable
------------------------------

### Concordance Status

When a patient's OAC exposure status was consistent with the decision aid's recommendation (OAC recommended---OAC exposed, OAC not recommended---OAC unexposed), that patient was considered to be concordant with the treatment recommendation of the respective decision aid. We also looked at the underuse and overuse of OAC (Underuse: OAC recommended-OAC unexposed; Overuse: OAC not recommended-OAC exposed) separately.

2.7. Analyses
-------------

We compared the demographic characteristics of OAC exposed and unexposed. Based on the CHA~2~DS~2~-VASc and HAS-BLED scores, AF patients were classified into nine categories to study the variation in treatment recommendations by the decision aids and their concordance with actual OAC use/non-use. These nine categories reflected the nine possible combinations of low, moderate and high CHA~2~DS~2~-VASc (low---CHA~2~DS~2~-VASc = 0; moderate CHA~2~DS~2~-VASc = 1; high---CHA~2~DS~2~-VASc \> 1) scores and HAS-BLED (low---HAS-BLED = 0; moderate HAS-BLED = 1 or 2; high---HAS-BLED ≥ 3) scores. The number of patients in each subgroup and their treatment recommendations were determined. In addition, the number and percent of patients discordant with the treatment recommendations by each decision aid were also determined. The decision aid recommendations and percent discordance with these recommendations were reported for the entire population to provide an overall acceptance of these decision aids. To assess the factors responsible for the difference in treatment recommendations and actual OAC use, we compared the characteristics of patients who were over-anticoagulated and under-anticoagulated based on the recommendations of each decision aid using a chi square test. Characteristics for comparison included age, gender, geographic region, prior stroke, hypertension, diabetes, heart failure, anemia, major bleed, renal failure, liver failure, vascular disease, alcohol use, medication use (anti-platelets, NASIDs, GI agents, antineoplastic agents, systemic corticosteroids), CHA~2~DS~2~-VASc score, CHADS~2~ score, ATRIA score and HAS-BLED score. All analyses were performed using SAS version 9.3 (SAS Institute Inc., Cary, NC, USA).

3. Results
==========

A total of 15,129 incident AF patients met our inclusion-exclusion criteria ([Table S2](#healthcare-03-00130-s001){ref-type="supplementary-material"}). Of these, 7668 (50.68%) were OAC exposed within first 90 days after the index diagnosis ([Table 1](#healthcare-03-00130-t001){ref-type="table"}). Compared to patients unexposed to OAC, a higher percentage of OAC exposed patients had CHA~2~DS~2~-VASc scores ≥2 (70.24% *vs.* 59.95%, *p* value \< 001; [Table 1](#healthcare-03-00130-t001){ref-type="table"} and [Table S3](#healthcare-03-00130-s001){ref-type="supplementary-material"}). Also, the proportion of patients with moderate to high HAS-BLED score was higher among the OAC exposed group compared to the OAC unexposed group (84.89% *vs.* 76.79%, *p* value \< 001). Actual OAC exposure was not always influenced by the baseline stroke and bleeding risks ([Figure 1](#healthcare-03-00130-f001){ref-type="fig"}).

The AHA Aggressive guideline recommended OAC most often (86.30%) and the LaHaye tool recommended OAC the least often (14.91%; [Table 2](#healthcare-03-00130-t002){ref-type="table"}). None of the decision aids recommended OAC for patients when CHA~2~DS~2~-VASc = 0. However, OAC treatment recommendations varied considerably when the stroke risk was moderate or high (CHA~2~DS~2~-VASc \> 0). For example, the LaHaye tool never recommended OAC for patients with CHA~2~DS~2~-VASc = 1 irrespective of bleeding risk, however, the ESC guidelines as we defined them universally recommended OAC for patients with CHA~2~DS~2~-VASc = 1 and a HAS-BLED \< 3. For those with the highest stroke risk, the ESC and AHA guidelines recommended OAC in all patients with CHA~2~DS~2~-VASc score ≥ 2 irrespective of the HAS-BLED score, whereas the CHEST guidelines, Casciano and LaHaye tools recommended OAC between 22.88% and 95.57% of high stroke risk patients.

healthcare-03-00130-t001_Table 1

###### 

Demographics characteristics of the study population.

  Characteristics                               OAC Exposed     OAC Unexposed   Total            *p* Value
  --------------------------------------------- --------------- --------------- ---------------- -----------
  **Number of patients (n %)**                  7668 (50.68%)   7461 (49.32%)   15129            
  **Mean age, y (SD)**                          65.04 (11.82)   62.54 (14.84)   63.81 (13.45)    \<0.001
                                                **N (%)**       **N (%)**       **N (%)**        
  **Age Category, y**                                                                            \<0.001
  18--30                                        29 (0.38%)      146 (1.96%)     175 (1.16%)      
  31--49                                        584 (7.62%)     1156 (15.49%)   1740 (11.50%)    
  50--64                                        3453 (45.03%)   3092 (41.44%)   6545 (43.26%)    
  65--74                                        1745 (22.76%)   1240 (16.62%)   2985 (19.73%)    
  75--84                                        1570 (20.47%)   1429 (19.15%)   2999 (19.82%)    
  ≥85                                           287 (3.74%)     398 (5.33%)     685 (4.53%)      
  **Gender**                                                                                     \<0.001
  Male                                          4961 (53.16%)   4372 (46.84%)   9333 (61.69%)    
  Female                                        2707 (35.30%)   3089 (41.40%)   5796 (38.31%)    
  **Geographic Region**                                                                          \<0.001
  East                                          1591 (20.75%)   1474 (19.76%)   3065 (20.26%)    
  Midwest                                       2656 (34.64%)   2454 (32.89%)   5110 (33.78%)    
  South                                         2301 (30.01%)   2271 (30.44%)   4572 (30.22%)    
  West                                          1120 (14.61%)   1262 (16.91%)   2382 (15.74%)    
  **Comorbidities**                                                                              
  Prior stroke or TIA                           551 (7.19%)     476 (6.38%)     1027 (6.79%)     0.048
  Hypertension                                  5177 (67.51%)   4263 (57.14%)   9440 (62.4%)     \<0.001
  Diabetes                                      1857 (24.22%)   1265 (16.95%)   3122 (20.64%)    \<0.001
  Heart failure                                 1506 (19.64%)   884 (11.85%)    2390 (15.8%)     \<0.001
  Anemia                                        731(9.53%)      864 (11.58%)    1595 (10.54%)    \<0.001
  History of any bleed                          675 (8.80%)     732 (9.81%)     1407 (9.30%)     0.032
  Renal impairment                              493 (6.43%)     441 (5.91%)     934 (6.17%)      0.185
  Liver failure                                 255 (3.33%)     258 (3.46%)     513 (3.39%)      0.652
  Vascular disease                              2377 (31.00%)   2202 (29.51%)   4579 (30.27%)    0.046
  Antiplatelet agents                           488 (6.36%)     403 (5.40%)     891 (5.89%)      0.011
  NASIDs                                        1443 (18.82%)   1208 (16.19%)   2651 (17.52%)    \<0.001
  GI agents                                     1532 (19.98%)   1398 (18.74%)   2930 (19.37%)    0.053
  Antineoplastic agents                         178 (2.32%)     135 (1.81%)     313 (2.07%)      0.027
  Systemic corticosteroids                      1136 (14.81%)   939 (12.59%)    2075 (13.72%)    \<0.001
  Alcohol use                                   124 (1.62%)     119 (1.59%)     243 (1.61%)      0.913
  **Stroke risk scores**                                                                         
  ***CHADS~2~ score***                                                                           \<0.001
  Low (score = 0)                               1524 (19.87%)   2426 (32.52%)   3950 (26.11%)    
  Medium (score = 1)                            2676 (34.90%)   2510 (33.64%)   5186 (34.28%)    
  High (score ≥ 2)                              3468 (45.23%)   2525 (33.84%)   5993 (39.61%)    
  ***CHA~2~DS~2~-VASc score***                                                                   \<0.001
  Low (score = 0)                               804 (10.49%)    1269 (17.01%)   2073 (13.70%)    
  Medium (score = 1)                            1478 (19.27%)   1719 (23.04%)   3197 (21.13%)    
  High (score ≥ 2)                              5386 (70.24%)   4473 (59.95%)   9859 (65.17%)    
  **Bleeding risk scores**                                                                       
  ***ATRIA score***                                                                              0.002
  Low (score ≤ 3)                               6590 (85.94%)   6391 (85.66%)   12981 (85.80%)   
  Medium (score = 4)                            596 (6.29%)     401 (5.37%)     883 (5.84%)      
  High (score ≥ 5)                              596 (7.77%)     669 (8.97%)     1265 (8.36%)     
  ***HAS BLED score***                                                                           \<0.001
  Low (score = 0)                               1159 (15.11%)   1731 (23.20%)   2890 (19.10%)    
  Medium (score = 1 or 2)                       4944 (64.48%)   4418 (59.21%)   9362 (61.88%)    
  High (score ≥ 3)                              1564 (20.41%)   1312 (17.58%)   2877 (19.02%)    
  **Anticoagulant exposure after index date**                                                    
  Warfarin                                      5886 (76.76%)   \-              5886 (38.91%)    
  Dabigatran                                    756 (9.86%)     \-              756 (5.00%)      
  Rivaroxaban                                   178 (2.32%)     \-              178 (1.18%)      
  Apixaban                                      5 (0.07%)       \-              5 (0.03%)        
  Antiplatelet agents                           365 (4.76%)     434 (5.82%)     799 (5.28%)      

SD, standard deviation, TIA: transient ischemic attack, NASIDs: Non-steroidal anti-inflammatory drugs, GI agents: Antacids, proton pump inhibitors, H2 receptor antagonist and other GI protectants, OAC/INR: use of oral anticoagulant or INR test with 90 days after index diagnosis.

The overall OAC exposure/non-exposure was most consistent with the Casciano tool (56.75%) and was least consistent with the LaHaye tool (49.94%; [Table S4](#healthcare-03-00130-s001){ref-type="supplementary-material"}). The overall percent discordance with the decision aid recommendations was fairly consistent over the study period ([Table S5](#healthcare-03-00130-s001){ref-type="supplementary-material"}). When the underuse of OAC was assessed using the nine stroke/bleed risk groups, underuse of OAC was similar between moderate and high stroke risk patients with OAC not being prescribed between 43.98% and 53.95% of patients recommended OAC ([Table 3](#healthcare-03-00130-t003){ref-type="table"}).

Most of the OAC unexposed patients who were recommended OAC by the decision aids had a high stroke risk profile (72.55%--100%; [Table S6](#healthcare-03-00130-s001){ref-type="supplementary-material"}). Since none of the decision aids recommended OAC use among patients with a low stroke risk, the percent of patients who were over-anticoagulated (38.78%) was consistent across all the decision aids at CHA~2~DS~2~-VASc score = 0 ([Table 4](#healthcare-03-00130-t004){ref-type="table"}).

Among the OAC exposed patients (*n* = 7668), the decision aids recommended withholding the OAC therapy in 10.49%--84.68% of the patients depending on the decision aid. Most of the patients (35.14%--100%) who were exposed to OAC when not recommended had low to moderate stroke risk profiles ([Table S7](#healthcare-03-00130-s001){ref-type="supplementary-material"}).

![Actual OAC use: Number of patients that received and did not receive OAC stratified by stroke and bleeding risk scores. \* Data shown are the number of patients who were exposed to OAC/non-OAC within 90 days after index diagnosis. Low stroke: CHA~2~DS~2~-VASc score = 0, Med stroke: CHA~2~DS~2~-VASc score = 1, high stroke: CHA~2~DS~2~-VASc score ≥ 2, Low bleed: HAS BLED score = 0, Med bleed: HAS BLED score = 1 or 2, high bleed: HAS BLED score ≥ 3).](healthcare-03-00130-g001){#healthcare-03-00130-f001}
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###### 

Oral anticoagulation (OAC) recommendations by the decision aid.

  Stroke Risk                               Bleeding risk                  AHA Aggressive   AHA Conservative   Casciano    CHEST       ESC         LaHaye
  ----------------------------------------- ------------------------------ ---------------- ------------------ ----------- ----------- ----------- --------
  **Low (CHA~2~DS~2~-VASc score = 0)**      **Low (HAS-BLED score = 0)**   0                0                  0           0           0           0
  n (%) = 1628 (10.76%)                     (0.00%)                        (0.00%)          (0.00%)            (0.00%)     (0.00%)     (0.00%)     
  **Medium (HAS-BLED score = 1 or 2)**      0                              0                0                  0           0           0           
  n (%) = 439(2.90%)                        (0.00%)                        (0.00%)          (0.00%)            (0.00%)     (0.00%)     (0.00%)     
  **High (HAS-BLED score ≥ 3)**             0                              0                0                  0           0           0           
  n (%) = 6 (0.04%)                         (0.00%)                        (0.00%)          (0.00%)            (0.00%)     (0.00%)     (0.00%)     
  **Sub-total**                             0                              0                0                  0           0           0           
  (0.00%)                                   (0.00%)                        (0.00%)          (0.00%)            (0.00%)     (0.00%)                 
  **Medium (CHA~2~DS~2~-VASc score = 1)**   **Low (HAS-BLED score = 0)**   1043             0                  193         196         1043        0
  n (%) = 1043(6.89%)                       (100%)                         (0.00%)          (18.50%)           (18.79%)    (100%)      (0.00%)     
  **Medium (HAS-BLED score = 1 or2)**       2093                           0                1371               1505        2093        0           
  n (%) = 2093(13.83%)                      (100%)                         (0.00%)          (65.50%)           (71.91%)    (100%)      (0.00%)     
  **High (HAS-BLED score ≥ 3)**             61                             0                19                 57          0           0           
  n (%) = 61 (0.40%)                        (100%)                         (0.00%)          (31.15%)           (93.44%)    (0.00%)     (0.00%)     
  **Sub-total**                             3197                           0                1583               1758        3136        0           
  (100%)                                    (0.00%)                        (49.51%)         (54.98%)           (98.09%)    (0.00%)                 
  **High (CHA~2~DS~2~-VASc score ≥ 2)**     **Low (HAS-BLED score = 0)**   219              219                151         158         219         219
  n (%) = 219 (1.45%)                       (100.00%)                      (100.00%)        (68.95%)           (72.15%)    (100.00%)   (100.00%)   
  **Medium (HAS-BLED score = 1 or 2)**      6830                           6830             5819               6468        6830        1102        
  n (%) = 6830 (45.15%)                     (100.00%)                      (100.00%)        (85.20%)           (94.70%)    (100.00%)   (16.13%)    
  **High (HAS-BLED score ≥ 3)**             2810                           2810             2210               2795        2810        935         
  n (%) = 2810 (18.57%)                     (100.00%)                      (100.00%)        (78.65%)           (99.47%)    (100.00%)   (33.27%)    
  **Sub-total**                             9859                           9859             8180               9421        9859        2256        
  (100.00%)                                 (100.00%)                      (82.96%)         (95.57%)           (100.00%)   (22.88%)                
  **Overall**                               **15129 (100%)**               13056            9859               9763        11179       12995       2256
  (86.30%)                                  (65.17%)                       (64.53%)         (73.89%)           (85.89%)    (14.91%)                

Data is presented as n (%) for oral anticoagulant recommendations by each decision aid. AHA Aggressive: AHA guidelines (assuming that guideline recommends OAC at CHA~2~DS~2~-VASc = 1), AHA Conservative: AHA guidelines (assuming that guideline recommends non-OAC at CHA~2~DS~2~-VASc = 1), Casciano: Casciano tool, CHEST: CHEST guidelines, ESC: ESC guidelines, LaHaye: LaHaye tool.
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###### 

Underuse of OAC (Number of patients discordant with the OAC treatment recommendation by decision aids).

  Stroke Risk                               Bleeding Risk                  AHA Aggressive      AHA Conservative    Casciano            CHEST               ESC                 LaHaye
  ----------------------------------------- ------------------------------ ------------------- ------------------- ------------------- ------------------- ------------------- -------------------
  **Low (CHA~2~DS~2~-VASc score = 0)\***    **Sub-total**                  ARNO                ARNO                ARNO                ARNO                ARNO                ARNO
  **Medium (CHA~2~DS~2~-VASc score = 1)**   **Low (HAS-BLED score = 0)**   640 (61.36%)        ARNO                52 (26.94%)         54 (27.55%)         640 (61.36%)        ARNO
  **Medium (HAS-BLED score = 1 or 2)**      1052 (50.26%)                  ARNO                661 (48.21%)        728 (48.37%)        1052 (50.26%)       ARNO                
  **High (HAS-BLED score ≥ 3)**             27 (44.26%)                    ARNO                8 (42.11%)          27 (47.37%)         ARNO                ARNO                
  **Sub-total**                             1719 (53.77%)                  ARNO                721 (45.55%)        809 (46.02%)        1692 (53.95%)       ARNO                
  **High (CHA~2~DS~2~-VAS score ≥ 2)**      **Low (HAS-BLED score = 0)**   90 (41.10%)         90 (41.10%)         47 (31.13%)         48 (30.38%)         90 (41.10%)         90 (41.10%)
  **Medium (HAS-BLED score = 1 or 2)**      3103 (45.43%)                  3103 (45.43%)       2578 (44.30%)       2904 (44.90%)       3103 (45.43%)       542 (49.18%)        
  **High (HAS-BLED score ≥ 3)**             1280 (45.55%)                  1280 (45.55%)       973 (44.03%)        1274 (45.58%)       1280 (45.55%)       449 (48.02%)        
  **Sub-total**                             4473 (45.37%)                  4473 (45.37%)       3598 (43.98%)       4226 (44.86%)       4473 (45.37%)       1081 (47.92%)       
  **Overall**                               **Total**                      **6192 (47.42%)**   **4473 (48.01%)**   **4319 (44.23%)**   **5035 (45.04%)**   **6165 (47.44%)**   **1081 (47.92%)**

Data is presented as n (%) of patients who are not consistent with the OAC treatment recommendation by each decision aid, ARNO: Always Recommends Non-OAC. \* Data not shown by bleed risk because no decision aids recommend OAC when CHA~2~DS~2~-VASc = 1 irrespective of HAS-BLED score. AHA Aggressive: AHA guidelines (assuming that guideline recommends OAC at CHA~2~DS~2~-VASc = 1), AHA Conservative: AHA guidelines (assuming that guideline recommends non-OAC at CHA~2~DS~2~-VASc = 1), Casciano: Casciano tool, CHEST: CHEST guidelines, ESC: ESC guidelines, LaHaye: LaHaye tool.
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###### 

Overuse of OAC (Number of patients discordant with the non-OAC treatment recommendation by decision aids).

  Stroke Risk                              Bleeding Risk                  AHA Aggressive     AHA Conservative    Casciano            CHEST               ESC                LaHaye
  ---------------------------------------- ------------------------------ ------------------ ------------------- ------------------- ------------------- ------------------ -------------------
  **Low (CHA~2~DS~2~-VASc score = 0)**     **Low (HAS-BLED score = 0)**   627 (38.51%)       627 (38.51%)        627 (38.51%)        627 (38.51%)        627 (38.51%)       627 (38.51%)
  **Medium (HAS-BLED score = 1 or 2)**     176 (40.09%)                   176 (40.09%)       176 (40.09%)        176 (40.09%)        176 (40.09%)        176 (40.09%)       
  **High (HAS-BLED score ≥ 3)**            1 (16.67%)                     1 (16.67%)         1 (16.67%)          1 (16.67%)          1 (16.67%)          1 (16.67%)         
  **Sub-total**                            804 (38.78%)                   804 (38.78%)       804 (38.78%)        804 (38.78%)        804 (38.78%)        804 (38.78%)       
  **Medium (CHA~2~DS~2~-VASc score = 1**   **Low (HAS-BLED score = 0)**   ARO                403 (38.64%)        262 (30.82%)        261 (30.81%)        ARO                403 (38.64%)
  **Medium (HAS-BLED score = 1 or 2)**     ARO                            1041 (49.74%)      331 (45.84%)        264 (44.90%)        ARO                 1041 (49.74%)      
  **High (HAS-BLED score ≥ 3)**            ARO                            34 (55.74%)        23 (54.76%)         4 (100.00%)         34 (55.74%)         34 (55.74%)        
  **Sub-total**                            ARO                            1478 (46.23%)      616 (38.17%)        529 (36.76%)        34 (55.73%)         1478 (46.23%)      
  **High (CHA~2~DS~2~-VASc score ≥ 2)**    **Low (HAS-BLED score = 0)**   ARO                ARO                 25 (36.76%)         19 (31.15%)         ARO                ARO
  **Medium (HAS-BLED score = 1 or 2)**     ARO                            ARO                486 (48.07%)        163 (45.03%)        ARO                 3167 (55.29%)      
  **High (HAS-BLED score ≥ 3)**            ARO                            ARO                293 (48.83%)        9 (60.00%)          ARO                 1044 (55.68%)      
  **Sub-total**                            ARO                            ARO                804 (47.88%)        191 (43.61%)        ARO                 4211 (55.38%)      
  **Overall**                              **Total**                      **804 (38.78%)**   **2282 (43.30%)**   **2224 (41.45%)**   **1564 (39.59%)**   **838 (39.27%)**   **6493 (50.43%)**

Data is presented as n (%) of patients who are not consistent with the non- OAC treatment recommendation by each decision aid. ARO: Always recommends OAC. AHA Aggressive: AHA guidelines (assuming that guideline recommends OAC at CHA~2~DS~2~-VASc = 1), AHA Conservative: AHA guidelines (assuming that guideline recommends non-OAC at CHA~2~DS~2~-VASc = 1), Casciano: Casciano tool, CHEST: CHEST guidelines, ESC: ESC guidelines, LaHaye: LaHaye tool.

4. Discussion
=============

There is a considerable variation in the treatment recommendations by the decision aids. The AHA and CHEST guidelines base their recommendations exclusively on the stroke risk algorithms, and these recommend OAC to more patients (65.17%--86.30%) compared to the LaHaye (14.91%) and Casciano (64.53%) tools which formally incorporate bleeding risk. The decision tools/guidelines which are based on the same stroke risk algorithm have more similarity in the treatment recommendations compared to those which are based on different stroke risk algorithms. For example, the treatment recommendations by the CHEST guidelines are more similar to the Casciano tool recommendations, both of which are based on the CHADS~2~ algorithm compared to the CHA~2~DS~2~VASc based ESC guideline and LaHaye tool. However, the treatment recommendations by the decisions aids based on the same stroke risk algorithm also differ depending on the weight given to the bleeding risk by the respective decision aids. For example, the LaHaye tool incorporates HAS-BLED score (0 to 7) at all levels of CHA~2~DS~2~VASc score (0 to 9) which is different than the ESC guidelines in which we only considered bleed risk to be a factor when CHA~2~DS~2~VASc = 1, which led to a 70.98% difference in OAC recommendations.

The treatment recommendations by the decision aids varied considerably among patients with moderate to high stroke risk. The stroke risk algorithm used and the weight given to the bleeding risk by respective decision aids mostly influences this variation. As the CHA~2~DS~2~-VASc algorithm accounts for additional stroke factors (vascular disease, female gender and age between 65 and 74 years) \[[@B18-healthcare-03-00130]\], the decision aids based on CHA~2~DS~2~-VASc classifies a higher proportion of patients in moderate and particularly in high stroke risk groups compared to the decision aids which are based on the CHADS~2~ algorithm. Although the LaHaye and the Casciano decision support tools consider bleeding risk algorithms in rendering OAC recommendations, both tools are based on different stroke risk and bleeding risk algorithms. Furthermore, the LaHaye tool recommendations are also influenced by bleed, treatment and cost thresholds while the Casciano tool recommendations are based on quality-adjusted life survival which incorporates demographic factors in addition to stroke and bleeding risk to render warfarin/aspirin treatment recommendations \[[@B9-healthcare-03-00130],[@B11-healthcare-03-00130]\].

Despite the recommendation of withholding OAC in patients with CHA~2~DS~2~-VASc = 0 by all the decision aids, we found considerable utilization of OAC in these patients. Nearly 40% of CHA~2~DS~2~-VASc = 0 patients were OAC exposed which is similar to the 43.1% found by Lip *et al.* suggesting that overutilization is a widespread and persistent problem \[[@B26-healthcare-03-00130]\].

Our study confirms that OACs are underused in patients with elevated stroke risk \[[@B3-healthcare-03-00130],[@B4-healthcare-03-00130],[@B5-healthcare-03-00130]\]. We found that depending on the decision aid, between 45% and 48% were NOT anticoagulated when recommended. Although the use of OACs reduces the risk of stroke in all patients, it also increases the risk of hemorrhagic events \[[@B11-healthcare-03-00130]\]. Therefore, both overuse and underuse can be viewed as a concern in terms of AF related adverse events. When compared with the "real world" data, we found that the direction of OAC misuse was in both directions, patients who were OAC treatment eligible (moderate-high stroke risk) were often not anticoagulated while patients who were not eligible for OAC treatment (moderate--high bleeding risk with low stroke risk) were anticoagulated. The reason for this discrepancy between the actual OAC use and guideline recommendations could be attributed to the difference in physicians' perceptions and empirical algorithms for risk assessment of stroke/bleed events. Hypertension, heart failure, age and diabetes have a smaller influence on physician assigned stroke risk while prior stroke, severe AF symptoms and not living independently have a higher influence on physician assigned stroke risk when compared to empirical stroke risk algorithms. \[[@B27-healthcare-03-00130]\] Our data had similar findings; patients who were under-anticoagulated had a high proportion of hypertensive patients (68.71%--84.67%), females (43.88%--72.43%), patients with vascular disease (35.56%--75.39%) and diabetes (20.43%--44.96%).

5. Limitations
==============

The newer oral anticoagulants were not available over most of the study time thereby limiting the study to more general OAC/non-OAC comparisons. We relied on the prescription claims supplemented by INR test to identify OAC exposure and 6.29% of patients were considered OAC exposed by INR tests alone and a portion of these patients may be misclassified. Furthermore, this study could not assess the degree of guideline concordance with aspirin recommendations. The database used for this study does not contain information on lab values for the INR/PT test, which is one of the risk factors to calculate the HAS-BLED score. The lack of information about this risk factor might underestimate the bleeding risk determined by HAS-BLED for those that are anticoagulated with warfarin over time. However, the aim of our study was to assess the appropriateness of initial anticoagulation, and the lack of information on labile INR would not significantly influence our study findings. When administrative claims data are used, coding errors could influence study measures. The accuracy of identifying the comorbid conditions used to calculate stroke/bleed risk scores using the administrative database has been previous validated (crude agreement: 78%--96%) \[[@B23-healthcare-03-00130],[@B28-healthcare-03-00130]\] however not all study measures have known validity \[[@B11-healthcare-03-00130],[@B24-healthcare-03-00130],[@B29-healthcare-03-00130]\]. Finally, the data is representative of a commercially insured population and the study findings may not be applicable for other populations.

6. Conclusions
==============

Real world OAC prescribing is frequently discordant with all the common contemporary guidelines and decision aids with both overuse and underuse of OAC being detected. There is a considerable variability in the OAC treatment recommendations by the AF guidelines and decision tools when the ischemic stroke risk is moderate or high. Given the variability in guideline recommendations, empirical evidence is needed to compare the outcomes of OAC treatment recommendations for these decision aids.
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